Tom 16, Nr 4 (2020)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2021-01-11
Przegląd piśmiennictwa
DOI: 10.5603/PPN.2020.0037
Pol. Przegl. Neurol 2020;16(4):251-252.
Streszczenie
Brak
Referencje
- Paliwal VK, Garg RK, Gupta A, et al. Neuromuscular presentations in patients with COVID-19. Neurol Sci. 2020; 41(11): 3039–3056.
- Fan H, Tang X, Song Y, et al. Influence of COVID-19 on cerebrovascular disease and its possible mechanism. Neuropsychiatr Dis Treat. 2020; 16: 1359–1367.
- Zheng C, Kar I, Chen CK, et al. Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic: implications on the risk of infection and future vaccination. CNS Drugs. 2020; 34(9): 879–896.
- Gklinos P. Neurological manifestations of COVID-19: a review of what we know so far. J Neurol. 2020; 267(9): 2485–2489.
- Kapica-Topczewska K, Collin F, Tarasiuk J, et al. Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland. Neurol Neurochir Pol. 2020; 54(2): 161–168.